Floatz logo

Everolimus

Post-transplant Lymphoproliferative Disorder

Mayo ClinicSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Post-transplant Lymphoproliferative Disorder cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Jennifer Amengual
Phase 2BBB
Cyclophosphamide
Washington University School of Medicine
Phase 2BBB
cc-5013
Northwestern University
Phase 2BB
Fludarabine
City of Hope Medical Center
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 49 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →